

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p style="text-align: center;">Licensee</p> <p>1. Franciscan Health Michigan City</p> <p>2. 301 W. Homer St. Michigan City, IN 46360</p>		<p>In accordance with letter dated February 07, 2018.</p> <p>3. License number: 13-13144-02 is amended in its entirety to read as follows:</p>	<p>4. Expiration Date: June 30, 2026</p> <p>5. Docket No.: 030-09928 Reference No.:</p>
<p>6. Byproduct, source, and/or special nuclear material</p> <p>A. Any byproduct material permitted by 10 CFR 35.100</p> <p>B. Any byproduct material permitted by 10 CFR 35.200</p> <p>C. Any byproduct material permitted by 10 CFR 35.300</p> <p>D. Iodine-125 permitted by 10 CFR 35.400</p>	<p>7. Chemical and/or physical form</p> <p>A. Any</p> <p>B. Any</p> <p>C. Any</p> <p>D. Sealed Sources (Bard Brachytherapy, Inc., Model STM 1251; Medi-Physics, Inc. d/b/a GE Healthcare, Model 6711 (OncoSeed))</p>	<p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>A. As Needed</p> <p>B. As Needed</p> <p>C. 1 curie total</p> <p>D. 1 curie total</p>	<p>9. Authorized use</p> <p>A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100.</p> <p>B. For use in imaging and localization studies permitted by 10 CFR 35.200.</p> <p>C. For any use permitted by 10 CFR 35.300.</p> <p>D. For any manual brachytherapy procedure permitted by 10 CFR 35.400.</p>

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
13-13144-02

Docket or Reference Number
030-09928

Amendment No. 49

CONDITIONS

10. Licensed material may be used or stored at the licensee's facilities located at:
 A. 301 W. Homer St., Michigan City, Indiana, 46360
 B. 8955 W. 400 North, Michigan City, Indiana, 46360
11. The Radiation Safety Officer (RSO) for this license is Richard L. Dobben, M.D.
12. Licensed material shall only be used by, or under the supervision of:
- A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.
- B. The following individuals are authorized users for the material and medical uses as indicated:

Authorized User(M.D.,D.O.,etc.)

Material and Use

Richard L. Dobben, M.D.

10 CFR 35.100, 35.200, and 35.300 (limited to the oral administration of sodium iodide I-131)

Mir J. Shah, M.D.

10 CFR 35.400

Peter John Georgis, M.D.

10 CFR 35.100, 35.200, and 35.300

Steven R. Klepac, M.D.

10 CFR 35.100 and 35.200

Jong-II Marcus Lee, M.D.

10 CFR 35.100, 35.200, and 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries)

Gregory Henkle, M.D.

10 CFR 35.100, 35.200, and 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries)

Matthew J. Rose, M.D.

10 CFR 35.100, 35.200, and 35.300 (limited to the oral administration of sodium iodide I-131)

Perry M. Gilbert, M.D.

10 CFR 35.100, 35.200, and 35.300

A. Melinda Liller, M.D.

10 CFR 35.100, 35.200, and 35.300

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
13-13144-02

Docket or Reference Number
030-09928

Amendment No. 49

Authorized User(M.D.,D.O.,etc.)

Joseph E. Judge, M.D.

Michael A. Wilczynski, D.O.

Mohammed A. Abbas, M.D.

Michael Flisak, M.D.

Garry Malnar, D.O.

Brendan Banyon, M.D.

Material and Use

10 CFR 35.100 and 35.200


10 CFR 35.100 and 35.200

10 CFR 35.100 and 35.200

10 CFR 35.100 and 35.300

10 CFR 35.100, 35.200, and 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries)

10 CFR 35.100, 35.200, and 35.300 (limited to the oral administration of sodium iodide I-131)




**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
13-13144-02

Amendment No. 49

Docket or Reference Number
030-09928


13. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Application dated December 8, 2015 (ML15344A470)
 - B. Letter dated May 18, 2016 (ML16144A585)
 - C. Letter dated May 15, 2017 (ML17139D193)



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: April 19, 2018

By: _____


Jennifer L. Bishop
Region 3